Adeona to Host Investor Day on CNS Diseases

ANN ARBOR, Mich., Sept. 23 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (Amex: AEN) announced today that it will host an investor day luncheon presentation at 12 Noon Eastern Time on Wednesday, September 29, 2010, in New York City.  

The keynote speaker will be David A. Newsome, M.D., FARVO, Adeona's Senior Vice President of Research and Development. Dr. Newsome has spent over a decade in clinical and laboratory research at the National Eye Institute, part of the National Institutes of Health, becoming the head of the Retinal Disease Section. While there, Dr. Newsome conceived of the "Zinc Hypothesis", that adding oral zinc as a supplement can slow the rate of vision loss from age-related macular degeneration. Dr. Newsome conducted the first prospective, randomized, placebo-controlled study of oral zinc supplementation in age-related macular degeneration, now the standard of care for millions of patients worldwide. Age-related macular degeneration is a disease affecting 10 million Americans and the leading cause of blindness in the older population. Dr. Newsome has authored approximately 160 peer-reviewed publications and several books. Dr. Newsome received his medical degree from Columbia University and completed an ophthalmology residency and a fellowship in retinal diseases and surgery at Harvard University. He also completed a retinal fellowship at the Bascom Palmer Eye Institute, University of Miami. 

Dr. Newsome's presentation on diseases of the central nervous system will focus on the scientific infrastructure of the treatments Adeona has in clinical development for Alzheimer's disease, multiple sclerosis, and dry age-related macular degeneration. Seating for the event is highly limited and by invitation only. Interested parties should contact Catherine Esposito at 212-732-4300 to request an invitation.

Webcast Information

A live audiovisual webcast of the presentation can be accessed by logging onto http://www.videonewswire.com/event.asp?id=72540 or by visiting the Company's website at www.adeonapharma.com beginning 12:00 Noon Eastern time on Wednesday, September 29, 2010. The webcast will be archived for at least 30 days following the presentation.

About Adeona Pharmaceuticals, Inc.

Adeona (AMEX:AEN - News) is a pharmaceutical company developing new medicines for serious central nervous systems diseases.  Our primary strategy is to license clinical-stage drug candidates that have already demonstrated a certain level of clinical efficacy and develop them to a valuation inflection point resulting in a significant development and marketing collaboration. We have four drug candidates and one medical food candidate in development. Further information on the company is available at www.adeonapharma.com.

SOURCE Adeona Pharmaceuticals, Inc.

Copyright . 23 PR Newswire